Literature DB >> 28385551

Down syndrome: age-dependence of PiB binding in postmortem frontal cortex across the lifespan.

Harry LeVine1, H Peter Spielmann2, Sergey Matveev3, Francesca Macchiavello Cauvi3, M Paul Murphy1, Tina L Beckett3, Katie McCarty3, Ira T Lott4, Eric Doran4, Frederick Schmitt5, Elizabeth Head6.   

Abstract

Beta-amyloid (Aβ) deposition in brain accumulates as a function of age in people with Down syndrome (DS) with subsequent development into Alzheimer disease neuropathology, typically by 40 years of age. In vivo imaging using the Pittsburgh compound B (PiB) ligand has facilitated studies linking Aβ, cognition, and dementia in DS. However, there are no studies of PiB binding across the lifespan in DS. The current study describes in vitro 3H-PiB binding in the frontal cortex of autopsy cases with DS compared to non-DS controls. Tissue from 64 cases included controls (n = 25) and DS (n = 39). In DS, 3H-PiB binding was significantly associated with age. After age 40 years in DS, 3H-PiB binding rose dramatically along with increasing individual variability. 3H-PiB binding correlated with the amount of Aβ42. Using fixed frontal tissue and fluorescent 6-CN-PiB, neuritic and cored plaques along with extensive cerebral amyloid angiopathy showed 6-CN-PiB binding. These results suggest that cortical PiB binding as shown by positron emission tomography imaging reflects plaques and cerebral amyloid angiopathy in DS brain.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  (3)H-X-34; Aging; Alzheimer disease; Beta-amyloid; Neurofibrillary tangles; Plaques; Thioflavine S; Trisomy 21

Mesh:

Substances:

Year:  2017        PMID: 28385551      PMCID: PMC5638297          DOI: 10.1016/j.neurobiolaging.2017.03.005

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  36 in total

Review 1.  Genetic and host factors for dementia in Down's syndrome.

Authors:  Nicole Schupf; Gertrude H Sergievsky
Journal:  Br J Psychiatry       Date:  2002-05       Impact factor: 9.319

Review 2.  Cerebrovascular contributions to aging and Alzheimer's disease in Down syndrome.

Authors:  Donna M Wilcock; Frederick A Schmitt; Elizabeth Head
Journal:  Biochim Biophys Acta       Date:  2015-11-26

3.  [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease.

Authors:  M A Mintun; G N Larossa; Y I Sheline; C S Dence; S Y Lee; R H Mach; W E Klunk; C A Mathis; S T DeKosky; J C Morris
Journal:  Neurology       Date:  2006-08-08       Impact factor: 9.910

4.  PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease.

Authors:  J Koivunen; A Verkkoniemi; S Aalto; A Paetau; J-P Ahonen; M Viitanen; K Någren; J Rokka; M Haaparanta; H Kalimo; J O Rinne
Journal:  Brain       Date:  2008-06-25       Impact factor: 13.501

Review 5.  The evolution of preclinical Alzheimer's disease: implications for prevention trials.

Authors:  Reisa Sperling; Elizabeth Mormino; Keith Johnson
Journal:  Neuron       Date:  2014-11-05       Impact factor: 17.173

Review 6.  Cognitive deficits and associated neurological complications in individuals with Down's syndrome.

Authors:  Ira T Lott; Mara Dierssen
Journal:  Lancet Neurol       Date:  2010-06       Impact factor: 44.182

Review 7.  Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology.

Authors:  Elizabeth Head; Ira T Lott; Donna M Wilcock; Cynthia A Lemere
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

8.  Correspondence between in vivo (11)C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques.

Authors:  Ira Driscoll; Juan C Troncoso; Gay Rudow; Jitka Sojkova; Olga Pletnikova; Yun Zhou; Michael A Kraut; Luigi Ferrucci; Chester A Mathis; William E Klunk; Richard J O'Brien; Christos Davatzikos; Dean F Wong; Susan M Resnick
Journal:  Acta Neuropathol       Date:  2012-08-05       Impact factor: 17.088

9.  Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents.

Authors:  Chester A Mathis; Yanming Wang; Daniel P Holt; Guo-Feng Huang; Manik L Debnath; William E Klunk
Journal:  J Med Chem       Date:  2003-06-19       Impact factor: 7.446

Review 10.  Brain imaging in Alzheimer disease.

Authors:  Keith A Johnson; Nick C Fox; Reisa A Sperling; William E Klunk
Journal:  Cold Spring Harb Perspect Med       Date:  2012-04       Impact factor: 6.915

View more
  13 in total

Review 1.  Neuropathological correlates of amyloid PET imaging in Down syndrome.

Authors:  Eric E Abrahamson; Elizabeth Head; Ira T Lott; Benjamin L Handen; Elliott J Mufson; Bradley T Christian; William E Klunk; Milos D Ikonomovic
Journal:  Dev Neurobiol       Date:  2019-08-17       Impact factor: 3.964

Review 2.  "Donating our bodies to science": A discussion about autopsy and organ donation in Turner syndrome.

Authors:  Siddharth K Prakash; Adrianna K San Roman; Melissa Crenshaw; Barbara Flink; Kimberly Earle; Evan Los; Åsa Bonnard; Angela E Lin
Journal:  Am J Med Genet C Semin Med Genet       Date:  2019-01-11       Impact factor: 3.908

3.  Frontal cortex and striatal cellular and molecular pathobiology in individuals with Down syndrome with and without dementia.

Authors:  Sylvia E Perez; Jennifer C Miguel; Bin He; Michael Malek-Ahmadi; Eric E Abrahamson; Milos D Ikonomovic; Ira Lott; Eric Doran; Melissa J Alldred; Stephen D Ginsberg; Elliott J Mufson
Journal:  Acta Neuropathol       Date:  2019-02-07       Impact factor: 17.088

Review 4.  Down syndrome, beta-amyloid and neuroimaging.

Authors:  Elizabeth Head; Alex M Helman; David Powell; Frederick A Schmitt
Journal:  Free Radic Biol Med       Date:  2017-09-19       Impact factor: 7.376

Review 5.  Cell models for Down syndrome-Alzheimer's disease research.

Authors:  Yixing Wu; Nicole R West; Anita Bhattacharyya; Frances K Wiseman
Journal:  Neuronal Signal       Date:  2022-04-08

6.  Altered connectivity of the default mode network in cognitively stable adults with Down syndrome: "Accelerated aging" or a prelude to Alzheimer's disease?

Authors:  H Diana Rosas; Lydia R Lewis; Nathaniel D Mercaldo; Shahin Nasr; Adam M Brickman; Viviana Siless; Michael Yassa; Mithra Sathishkumar; Ira Lott; Nicole Schupf; Wayne Silverman; Florence Lai
Journal:  Alzheimers Dement (Amst)       Date:  2021-05-20

7.  High-resolution functional connectivity of the default mode network in young adults with down syndrome.

Authors:  Katherine A Koenig; Lynn M Bekris; Stephen Ruedrich; Grace E Weber; Maria Khrestian; Se-Hong Oh; Sanghoon Kim; Z Irene Wang; James B Leverenz
Journal:  Brain Imaging Behav       Date:  2020-10-18       Impact factor: 3.224

Review 8.  Metabolic and Vascular Imaging Biomarkers in Down Syndrome Provide Unique Insights Into Brain Aging and Alzheimer Disease Pathogenesis.

Authors:  Elizabeth Head; David K Powell; Frederick A Schmitt
Journal:  Front Aging Neurosci       Date:  2018-06-21       Impact factor: 5.750

9.  Regional binding of tau and amyloid PET tracers in Down syndrome autopsy brain tissue.

Authors:  L Lemoine; A Ledreux; E J Mufson; S E Perez; G Simic; E Doran; I Lott; S Carroll; K Bharani; S Thomas; A Gilmore; E D Hamlett; A Nordberg; A C Granholm
Journal:  Mol Neurodegener       Date:  2020-11-23       Impact factor: 14.195

Review 10.  Neuroimaging and other modalities to assess Alzheimer's disease in Down syndrome.

Authors:  Natalie Neale; Concepcion Padilla; Luciana Mascarenhas Fonseca; Tony Holland; Shahid Zaman
Journal:  Neuroimage Clin       Date:  2017-11-06       Impact factor: 4.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.